Does the REGENETEN Implant Actually Improve Rotator Cuff Repair Outcomes?

Overview

REGENETEN is a resorbable collagen implant placed on the cuff to augment a repair or induce tissue growth over a partial tear. It is FDA-cleared as a Class II mesh, not approved through a clinical-efficacy pathway. Trial evidence shows it reduces retear on MRI, but patients getting it did not report better function than those who didn't.

That gap between imaging and patient-reported results is the central honest tension on this page, and it is covered in detail below (FDA 510(k) K222501).

Who this is for

REGENETEN is most often used in two settings in this practice: as an augmentation added to a standard suture-anchor repair of a full-thickness tear, and as a standalone treatment placed over a partial-thickness tear that doesn't yet meet the threshold for a formal takedown-and-repair. It is not a substitute for a real repair in a large, retracted, full-thickness tear — the implant is a tissue-inductive scaffold, not a load-bearing construct, and it has not been studied as a way to avoid repairing a tear that needs repairing.

Reasonable candidates include patients with a repairable full-thickness tear where the surgeon wants additional biologic support for the repair, and patients with a high-grade partial-thickness tear whose tendon has not yet failed enough to require takedown and repair. It is not appropriate for patients being counseled about a massive or chronic tear with poor tissue quality, and it should not be sold to a patient as a way to guarantee a better-feeling shoulder — the evidence doesn't support that claim yet. Dr. Raffo discusses this option with patients from across Montgomery County, including Bethesda and Germantown, as part of a broader conversation about surgical and biologic options for cuff tears.

How I approach it

I use REGENETEN selectively, and I tell patients exactly what it has and hasn't been shown to do. The one Level I randomized trial we have found that adding the implant to a standard transosseous-equivalent repair cut the 12-month retear rate from 25.8% to 8.3% — roughly a two-thirds relative reduction (RR 0.32, 95% CI 0.13–0.83, P=.010) (Ruiz Ibán, Arthroscopy 2024), and that advantage held up at two years (35.1% versus 12.3% retear, P=.004) (ASES 2024 annual meeting paper). That is a real, reproducible structural effect and I don't discount it.

What I won't do is oversell it. In that same trial, the proportion of patients who reached a clinically meaningful improvement in outcome scores was statistically identical between groups — 76.7% versus 81.7% for Constant-Murley (P=.654), and 75% versus 80% for ASES (P=.829) (Ruiz Ibán, Arthroscopy 2024). The implant improved what shows up on the MRI. It did not, at least in this trial and at this time point, improve what the patient reported feeling. I tell patients that plainly: the tendon looks more intact, but two years out, the people who got it and the people who didn't felt about the same.

The operation

For augmentation of a standard repair, the implant is applied over the top of the repaired tendon after the primary suture-anchor fixation is complete, typically secured with a small number of additional anchors or sutures so it sits directly on the bursal surface of the cuff. For standalone use in a partial-thickness tear, the implant is placed directly onto the intact bursal surface without taking down or repairing the tendon itself, and it is meant to stimulate new tissue growth into the existing tendon over the following months. In both settings, the implant is resorbable and is not visible on imaging as a foreign material once incorporation occurs; what is tracked on follow-up MRI is tendon thickness and continuity.

Risks and honest tradeoffs

The evidence base for REGENETEN is a genuine mix of strong and weak signals, and both deserve equal weight. The strong part: a Level I RCT showing a large, statistically significant reduction in radiographic retear, from 25.8% to 8.3% at one year and maintained at two years (Ruiz Ibán, Arthroscopy 2024). The weak part: the same trial found no difference in the proportion of patients reaching a clinically meaningful improvement in Constant-Murley or ASES scores, and no difference in complication rates between groups (Ruiz Ibán, Arthroscopy 2024).

Much of the remaining published support for the implant comes from single-arm registry data and small prospective series rather than controlled comparisons — a 272-patient registry with strong before-and-after outcome improvement but no control group (Bushnell, Orthopaedic Journal of Sports Medicine 2021), a 33-patient prospective cohort showing tissue fill-in on MRI in 95–100% of tears with only one progressing to full thickness (Schlegel, JSES 2021), and a 32-patient series reporting 0% retear at 12 months (Yoo, Medicina 2025). A broader systematic review of 17 studies and 1,062 tears found reported retear rates ranging widely, from 0% to 18% at five years for partial-thickness tears treated with the implant and 0% to 35% at two years for full-thickness tears (Benthami Kbibi, Acta Orthopaedica Belgica 2024) — a wide enough range that it should not be read as a guaranteed result. The device's regulatory pathway is also worth stating plainly: 510(k) clearance as a Class II surgical mesh is a substantial-equivalence finding, not an FDA determination of clinical efficacy (FDA 510(k) K222501).

Recovery and rehabilitation

Recovery after a REGENETEN-augmented repair follows the same general timeline as a standard rotator cuff repair, because the implant does not change the fundamental biology of tendon-to-bone healing or the need to protect the repair during that process. Most patients wear a sling for four to six weeks, begin passive motion early, and progress to active motion and strengthening over the following two to three months, reaching functional strength by four to six months in most cases (OrthoInfo: Rotator Cuff Tears — Surgical Treatment Options). When the implant is used standalone over a partial-thickness tear without a formal repair, the protocol is typically less restrictive, since there is no anchor-based repair construct to protect, but the tendon still needs time to incorporate the new collagen scaffold — imaging in one study showed continued tendon thickening out to two years (Schlegel, JSES 2021).

Recovery milestones:

• Weeks 0–6: Sling protection; passive range of motion started, following the same protocol as the underlying repair.
• Weeks 6–8: Progression to active-assisted and active motion.
• Weeks 8–12: Strengthening program begins.
• Months 4–6: Functional motion and strength typically restored.
• Up to 2 years: Continued tendon remodeling and thickening on imaging has been documented out to two years in implant-augmented partial-thickness tears (Schlegel, JSES 2021).

1. Weeks 0–6

   Sling protection; passive range of motion started, following the same protocol as the underlying repair.

2. Weeks 6–8

   Progression to active-assisted and active motion.

3. Weeks 8–12

   Strengthening program begins.

4. Months 4–6

   Functional motion and strength typically restored.

5. Up to 2 years

   Continued tendon remodeling and thickening on imaging has been documented out to two years in implant-augmented partial-thickness tears (Schlegel, JSES 2021).

Alternatives I considered

For a full-thickness tear, the real alternative to REGENETEN augmentation is simply a standard repair without it — still the majority of what's done in this practice, and still a well-established procedure with predictable outcomes on its own. Platelet-rich plasma is another biologic option some patients ask about; meta-analyses show a modest reduction in retear with PRP (roughly 13–16.5% versus 18–23.6% without) but, similarly to REGENETEN, little to no consistent improvement in patient-reported outcome scores (meta-analysis; meta-analysis, 2025). I don't present either biologic as a way to guarantee a better result — I present both as reasonable, evidence-supported add-ons with a real but limited and still-developing evidence base.

Biologics used